Clik here to view.
Molecular Partners DME data published in AJO
Closely held Molecular Partners of Switzerland said results of a Phase 1/2 study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with diabetic...
View ArticleClik here to view.
Eyes on Ohr Pharma wet AMD study
Even though Ohr Pharmaceutical (OTCBB:OHRP) will be releasing results, in the current quarter, of a Phase 2 clinical trial in patients with cancer cachexia, all eyes are on a Phase 2 study of its...
View ArticleClik here to view.
Analysts initiate coverage of Ophthotech
Analysts with Leerink Swann and Stifel Nicholas have initiated coverage of Ophthotech (NASDAQ:OPHT), citing the potential vision benefits the company’s Fovista treatment for the wet form of age-related...
View ArticleClik here to view.
Mati Therapeutics isn’t your traditional biotech startup
Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to...
View ArticleClik here to view.
QLT to merge into Auxilium Pharma
One of Canada’s iconic drug developers, QLT (NASDAQ:QLTI; TSX:QLT), which developed the first treatment for wet age-related macular degeneration, is disappearing through a merger with Auxilium...
View ArticleClik here to view.
Molecular Partners, Allergan moving DARPin into Phase 3
Closely held Molecular Partners AG said that results from the Allergan-sponsored, double-masked stage 3 Phase 2 study of the DARPin abicipar pegol, for wet age-related macular degeneration (AMD)...
View ArticleClik here to view.
AMD Insight licenses AMD test from ArcticDx
Closely held AMD Insight has licensed the exclusive Canadian commercial rights to Macula Risk PGx from the test’s developer, ArcticDx. Macula Risk PGx is a combined prognostic and pharmacogenetic DNA...
View ArticleClik here to view.
Ocular Therapeutix eyeing sustained drug delivery
Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic...
View ArticleClik here to view.
Ohr Pharma stock tumbles on Phase 2 trial results
Ohr Pharmaceutical’s (NASDAQ:OHRP) experimental eye drug failed the main goal as a combination therapy in a mid-stage study, sending the company’s shares plunging 67% in the afternoon session on...
View ArticleClik here to view.
HCW starts StemCells at buy
H.C. Wainwright has launched coverage of StemCells (NASDAQ:STEM) with a “buy” rating and using a discounted cash flow analysis to derive a price target of $1. The stock closed at 62 cents on Friday....
View ArticleClik here to view.
Roth starts Tracon Pharma at buy
Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF...
View ArticleClik here to view.
BioLight Life Sciences focusing on ophthalmic portfolio
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as...
View ArticleClik here to view.
Circadian to expand product development portfolio
Australia’s Circadian Technologies (ASX:CIR), which has been advancing its lead drug candidate, VGX-100, as a treatment for cancer and eye diseases, is considering a move to expand its pipeline by...
View ArticleClik here to view.
Molecular Partners, Allergan moving DARPin into Phase 3
Closely held Molecular Partners AG said that results from the Allergan-sponsored, double-masked stage 3 Phase 2 study of the DARPin abicipar pegol, for wet age-related macular degeneration (AMD)...
View ArticleClik here to view.
Roth starts Tracon Pharma at buy
Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF...
View ArticleClik here to view.
Stifel starts Clearside Biomedical at buy
Stifel has launched coverage of Clearside Biomedical (NASDAQ:CLSD) with a “buy” rating and 12-month target price of $13. The stock closed at $6.80 on Friday. Clearside has developed a novel ocular...
View ArticleClik here to view.
Ocutrx augmented reality headset helping AMD patients see clearly
Michael Freeman, Founder & President California-based Ocutrx Vision Technologies has developed an augmented reality (AR) headset that helps age-related macular degeneration (AMD) patients overcome...
View ArticleClik here to view.
Outlook Therapeutics completes enrollment in Phase 3 wet AMD trial
Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD)....
View ArticleClik here to view.
LumiThera enrolls first patient in U.S. multi-center trial in dry AMD
Closely-held LumiThera enrolled the first patient in its multi-center U.S. clinical trial in patients with dry age-related macular degeneration (AMD). The study, called LIGHTSITE III, will evaluate...
View Article
